Fig. 4.
CD362+ human mesenchymal stromal cells (hMSCs) modulate the immune response after Escherichia coli–induced lung injury. CD362+ and heterogeneous hMSCs, but not CD362− cells, attenuated the increase in bronchoalveolar lavage (BAL) tumor necrosis factor (TNF) α concentrations (A), while all three cell types attenuated the increase in BAL interleukin (IL) 1β concentrations (B). (C) There was no effect of hMSC therapy on BAL IL 6 concentrations. CD362+, CD362−, and heterogeneous hMSCs each decreased BAL cytokine-induced neutrophil chemoattractant 1 (CINC-1; D), increased BAL IL 10 concentrations (E), and increased BAL keratinocyte growth factor (F) compared to treatment with vehicle alone (vehicle). Error bars represent SD. n = 10 animals per group. *Significantly (P < 0.05) different from vehicle control group.

CD362+ human mesenchymal stromal cells (hMSCs) modulate the immune response after Escherichia coli–induced lung injury. CD362+ and heterogeneous hMSCs, but not CD362− cells, attenuated the increase in bronchoalveolar lavage (BAL) tumor necrosis factor (TNF) α concentrations (A), while all three cell types attenuated the increase in BAL interleukin (IL) 1β concentrations (B). (C) There was no effect of hMSC therapy on BAL IL 6 concentrations. CD362+, CD362−, and heterogeneous hMSCs each decreased BAL cytokine-induced neutrophil chemoattractant 1 (CINC-1; D), increased BAL IL 10 concentrations (E), and increased BAL keratinocyte growth factor (F) compared to treatment with vehicle alone (vehicle). Error bars represent SD. n = 10 animals per group. *Significantly (P < 0.05) different from vehicle control group.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal